Somatic Transgenesis

sCD4 Is a Convenient Model for In Vivo Delivery of Soluble Proteins

Published in Gene Therapy Weekly, July 24th, 1995

Researchers have demonstrated, for the first time, that one potentially therapeutic protein can remain present in vivo for 60 days after a single somatic transgenesis.

Somatic transgenesis can be used to confer endogenous production of proteins that have therapeutic characteristics. One such product, sCD4, is known to efficiently inhibit HIV-1 in vitro. Because of its short half-life in vivo, however, it has impaired long-term clinical trials in patients with AIDS.

T. Valere, Institut Cochin de Genetique Moleculaire, Paris, France, and colleagues used a retroviral vector to introduce cDNA of sCD4 into primary mouse fibroblasts ("Continuous...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (1995-07-24)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry